Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genscript Biotech (GNNSF)
OTHER OTC:GNNSF
Genscript Biotech (GNNSF) Stock Price & Analysis
16 Followers
GNNSF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.98 - $3.22
Previous Close$1.68
Volume300.00
Average Volume (3M)202.39K
Market Cap
$3.54B
Enterprise Value$2.65B
Total Cash (Recent Filing)$1.26B
Total Debt (Recent Filing)$229.23M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Aug 28, 2024EPS Estimate
-$0.01Last Dividend Ex-Date
Jun 18, 2020Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding2,124,027,670
10 Day Avg. Volume1,600
30 Day Avg. Volume202,392
Standard Deviation0.19
R-Squared0.04
Alpha0.00129
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.73
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2.50Price Target Upside56.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Genscript Biotech News
PremiumCompany Announcements
Genscript Reports Strong CARVYKTI® Sales in Q2
PremiumCompany Announcements
Genscript Biotech Notes Unexplained Stock Fluctuations
PremiumCompany Announcements
Genscript Biotech Confirms Share Grant DetailsPremiumCompany Announcements
Genscript Biotech Issues Shares to Incentivize ConsultantsPremiumCompany Announcements
Genscript Biotech Reveals Board Structure
PremiumCompany Announcements
Genscript Biotech Announces Board Reshuffle
PremiumCompany Announcements
Genscript Subsidiary’s Landmark Trial SuccessPremiumCompany Announcements
Genscript Biotech Receives $30M Milestone PaymentOptions Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
1.77% Mutual Funds
4.37% Other Institutional Investors
93.85% Public Companies and
Individual Investors
GNNSF FAQ
What was Genscript Biotech’s price range in the past 12 months?
Genscript Biotech lowest stock price was $0.98 and its highest was $3.22 in the past 12 months.
What is Genscript Biotech’s market cap?
Currently, no data Available
When is Genscript Biotech’s upcoming earnings report date?
Genscript Biotech’s upcoming earnings report date is Aug 28, 2024 which is in 37 days.
How were Genscript Biotech’s earnings last quarter?
Genscript Biotech released its earnings results on Mar 10, 2024. The company reported -$0.063 earnings per share for the quarter, missing the consensus estimate of -$0.05 by -$0.013.
Is Genscript Biotech overvalued?
According to Wall Street analysts Genscript Biotech’s price is currently Undervalued.
Does Genscript Biotech pay dividends?
Genscript Biotech pays a Notavailable dividend of $0.01 which represents an annual dividend yield of N/A. See more information on Genscript Biotech dividends here
What is Genscript Biotech’s EPS estimate?
Genscript Biotech’s EPS estimate is -$0.01.
How many shares outstanding does Genscript Biotech have?
Genscript Biotech has 2,127,686,500 shares outstanding.
What happened to Genscript Biotech’s price movement after its last earnings report?
Genscript Biotech reported an EPS of -$0.063 in its last earnings report, missing expectations of -$0.05. Following the earnings report the stock price went down -8.155%.
Which hedge fund is a major shareholder of Genscript Biotech?
Currently, no hedge funds are holding shares in GNNSF
---
Genscript Biotech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.50 (56.25% Upside)
$2.50 (56.25% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.99%
12-Months-Change
Fundamentals
Return on Equity
-7.95%
Trailing 12-Months
Asset Growth
33.02%
Trailing 12-Months
Company Description
Genscript Biotech
Genscript Biotech Corp an investment holding company. It is involved in fundamental life sciences research, translational biomedical research, and early-stage pharmaceutical development businesses. The company segments include bio-science services and products, biologics development services, industrial synthetic biology products, and cell therapy. It generates maximum revenue from the bio-science services and products. Geographically, it derives majority revenue from North America and also has a presence in Europe, China, Asia Pacific, Japan, and Other Countries.
---
GNNSF Stock 12 Month Forecast
Average Price Target
$2.50
▲(56.25% Upside)
Technical Analysis
Best Analysts Covering GNNSF
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-30.00%
reiterated a buy rating 4 months ago
Copying Ziyi Chen's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -30.00% per trade.
---